Opdivo's commercial potential will likely take a hit in the wake of new Keytruda data, but the impact may depend on the ability of BMS to market the message that its I-O/I-O combo allows patients to delay chemo.
from Most popular articles from Medical Marketing and Media https://ift.tt/2KtYjr5
No comments:
Post a Comment